

(Signature)

13. (Twice amended) The method of claim 10, wherein the omega-3 fatty acid formulation comprises ethyl-EPA, ethyl-DHA, or both.

14. (Amended) An oral pharmaceutical composition comprising 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) in its free form and at least one omega-3 fatty acid.

15. (Amended) The oral pharmaceutical composition of claim 14 and further comprising ✓
a pharmaceutically acceptable carrier.

16. (Twice amended) The oral pharmaceutical composition of claim 14 wherein the daily dose of 13-HODE is equal to or less than 100 mg.

17. (Amended) The oral pharmaceutical composition of claim 15, wherein the carrier is a
mono-, di- or triglyceride oil.

18. (Amended) The oral pharmaceutical composition of claim 15, wherein the carrier is selected from the group consisting of corn, sunflower, safflower, cottonseed, grape seed, olive, evening primrose, borage, fish body, and fish liver oils.

19. (Amended) The oral pharmaceutical composition of claim 15, wherein the carrier is an ester of a fatty acid containing 16-26 carbon atoms and one or more double bonds.

*b2
b3y*

20. (Amended) The oral pharmaceutical composition of claim 15, wherein the carrier is selected from the group consisting of ethyl-eicosapentaenoic (ethyl-EPA), oleic, linoleic, alpha-linolenic, stearidonic, gamma-linolenic, dihomogammalinolenic, arachidonic, docosapentaenoic and docosahexaenoic (ethyl-DHA).

21. (Twice amended) The oral pharmaceutical composition of claim 14 wherein the composition is administered in the form selected from the group consisting of tablets, dragees, capsules, granules, solutions, suspensions and lyophilized compositions.

22. (Twice amended) The oral pharmaceutical composition of claim 14 wherein the composition further comprises a fat-soluble antioxidant selected from the group consisting of ascorbyl palmitate, tocopherols, and ascorbic acid in the presence of lecithin.

23. (Twice amended) The oral pharmaceutical composition of claim 14 wherein the composition further comprises an additive selected from the group consisting of aggregants, disaggregants, osmotic pressure regulating salts, buffers, sweeteners, and coloring agents.

b3y

25. (Amended) The oral pharmaceutical composition of claim 14, wherein the omega-3 fatty acid is selected from the group consisting of EPA, DHA, a derivative of EPA, and a derivative of DHA.

26. (Amended) The oral pharmaceutical composition of claim 14, wherein the omega-3 fatty acid is selected from the group consisting of ethyl-EPA and ethyl-DHA.